A Phase I, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Telbivudine (LDT600) in Children and Adolescents With Chronic Hepatitis B.

Trial Profile

A Phase I, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Telbivudine (LDT600) in Children and Adolescents With Chronic Hepatitis B.

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Telbivudine (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 20 Mar 2012 Additional trial locations added as reported by European Clinical Trials Database.
    • 09 May 2011 Planned End Date changed from 1 Apr 2010 to 1 May 2012 as reported by ClinicalTrials.gov.
    • 09 Dec 2009 Planned end date (1 Apr 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top